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Abstract
It is well established that HIV-1 infection typically involves an interaction between the viral envelope protein
gp120/41 and the CD4 molecule followed by a second interaction with a chemokine receptor, usually CCR5 or
CXCR4. In the early stages of an HIV-1 infection CCR5 using viruses (R5 viruses) predominate. In some viral subtypes
there is a propensity to switch to CXCR4 usage (X4 viruses). The receptor switch occurs in ~ 40% of the infected
individuals and is associated with faster disease progression. This holds for subtypes B and D, but occurs less
frequently in subtypes A and C. There are several hypotheses to explain the preferential transmission of R5 viruses
and the mechanisms that lead to switching of co-receptor usage; however, there is no definitive explanation for
either. One important consideration regarding transmission is that signaling by R5 gp120 may facilitate transmis-
sion of R5 viruses by inducing a permissive environment for HIV replication. In the case of sexual transmission,
infection by HIV requires the virus to breach the mucosal barrier to gain access to the immune cell targets that it
infects; however, the immediate events that follow HIV exposure at genital mucosal sites are not well understood.
Upon transmission, the HIV quasispecies that is replicating in an infected donor contracts through a “genetic bot-
tleneck”, and often infection results from a single infectious event. Many details surrounding this initial infection
remain unresolved. In mucosal tissues, CD4
+ T cells express high levels of CCR5, and a subset of these CD4
+/CCR5
high cells express the integrin a4b7, the gut homing receptor. CD4
+/CCR5
high/ a4b7
high T cells are highly
susceptible to infection by HIV-1 and are ideal targets for an efficient productive infection at the point of transmis-
sion. In this context we have demonstrated that the HIV-1 envelope protein gp120 binds to a4b7 on CD4
+ T cells.
On CD4
+/CCR5
high/ a4b7
high T cells, a4b7 is closely associated with CD4 and CCR5. Furthermore, a4b7 is ~3 times
the size of CD4 on the cell surface, that makes it a prominent receptor for an efficient virus capture. gp120-a4b7
interactions mediate the activation of the adhesion-associated integrin LFA-1. LFA-1 facilitates the formation of vir-
ological synapses and cell-to-cell spread of HIV-1. gp120 binding to a4b7 is mediated by a tripeptide located in the
V1/V2 domain of gp120. Of note, the V1/V2 domain of gp120 has been linked to variations in transmission fitness
among viral isolates raising the intriguing possibility that gp120-a4b7 interactions may be linked to transmission
fitness. Although many details remain unresolved, we hypothesize that gp120-a4b7 interactions play an important
role in the very early events following sexual transmission of HIV and may have important implication in the
design of vaccine strategies for the prevention of acquisition of HIV infection
Introduction
Infection by HIV-1 causes a profound depletion of CD4
+
T cells. This depletion eventually leads to the progres-
sion of HIV disease ultimately resulting in AIDS. The
selective targeting of CD4
+ T cells led to the seminal
discovery that the CD4 receptor itself is the principal
receptor targeted by HIV-1 [1,2]. To enter and infect a
permissive cell, HIV-1 requires CD4 [1,2] and the che-
mokine coreceptors CCR5 or CXCR4 [3,4]. The chemo-
kine receptor CCR5 is the predominant fusion cofactor
for most transmitted HIV-1 strains [5].
Gp120 exhibits a specific affinity for integrin a4b7
In the acute phase of infection after viral replication
reaches high levels HIV-1 (in the case of humans) and
SIV (in the case of non-human primates) destroy the
majority of CD4
+ T cells in draining lymphoid tissue,
particularly gut-associated lymphoid tissue (GALT)
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any medium, provided the original work is properly cited.[6-8]. This structural and functional damage is accom-
panied by nonspecific systemic immune activation and
cell death [9,10] and many events surrounding HIV-1
replication in GALT have been elucidated [11-13].
Recently, we raised a new set of questions related to
acute infection when we demonstrated that some HIV-1
isolates bind to and signal through integrin a4b7 [14],
the gut homing receptor.
a4b7 facilitates the migration of lymphocytes from gut
inductive sites (Peyer’s patches and mesenteric lymph
nodes) to the lamina propria [15]. These sites within
GALT play central roles in the initial phases of infection
following sexual transmission. a4b7
+/CD4
+ T cells have
also been detected in genital mucosa [16-19], where
CD4
+ T cells are initially infected at the time of HIV
transmission [6]. In this respect a4b7 provides a link
between the earliest site of infection and gut inductive
sites. Viruses isolated from acutely infected individuals
replicate primarily in CD4
+ T cells [20]. At the portal of
infection in the female genital tract, i.e.vaginal, ecto-
and endo-cervical tissues, CD4
+ T-cells are dispersed
within a few focal aggregates [21]. The early foci of
infected CD4
+ T cells are formed shortly after transmis-
sion and appear as small clusters of infected founder
populations [22]. Within days, infected cells migrate
from the genital mucosa to Peyer’s patches and mesen-
teric lymph nodes where high-level HIV replication
occurs [6,23]. It is clear that a4b7 is functionally linked
to each of the sites involved in the earliest phases of
acute infection.
Unlike the HIV-1 entry receptors (CD4 and CCR5),
a4b7 is not required for viral replication in vitro.Y e t ,
the explicit linkage between a4b7, Peyer’s patches,
mesenteric lymph nodes, lamina propria and the earliest
phases of acute infection, suggests that gp120-a4b7
interactions play an important role at an early point in
HIV infection in vivo. Supporting this proposition, a4b7
reactivity is conserved across gp120s from the four
major HIV-1 subtypes. gp120 binding to a4b7 is
mediated by a conserved tripeptide in the V2-loop. This
tripeptide mimics a related tripeptide encoded by the
natural ligands of a4b7[24]. This structural mimicry,
along with the high degree of conservation across sub-
types, implies that binding to a4b7 confers a replication
advantage to HIV-1. A detailed understanding of the
events surrounding transmission provide important
c l u e sa st oh o wH I V - 1i su t i l i z i n ga4b7 during the ear-
liest days of infection in a new host.
Numerous barriers reduce the efficiency of mucosal
transmission. Studies of couples discordant for HIV
infection have demonstrated that heterosexual transmis-
sion is very inefficient since multiple exposures typically
precede successful transmission [25,26]. Given that sex-
ual transmission is inefficient, and our determination
that a4b7 CD4
+ T cells are highly susceptible to produc-
tive infection [16] it is reasonable to assume that the
ability of a virus to bind to a4b7 m a yb ep a r t i c u l a r l y
relevant at an early stage of infection. Because different
isolates of HIV-1 vary greatly in their a4b7 reactivity it
is possible that viral isolates that exhibit optimal a4b7
reactivity are able to establish infection more efficiently.
Specifically, the affinity of gp120 for a4b7 provides a
mechanism for HIV-1 to target a subset of CD4
+ T cells
that are highly susceptible to infection. Such an activity
may be particularly critical during transmission.
a4b7 and CCR5 are coexpressed on a CD4
+ T-cell
subset that is highly susceptible to infection,
which may favor the transmission of R5 viruses
a4b7 is upregulated on activated CD4
+ T cells localized
within mucosal tissues that are highly relevant to HIV-1
pathogenesis: Peyer’s patches, mesenteric lymph nodes,
lamina propria, and genital mucosa [15,16,19,27,28].
These cells also express high levels of CCR5, and there-
fore represent an ideal target population for productive
infection. On these cells a4b7 is closely associated with
both CD4, the HIV-1 entry receptor [16] (Fig. 1) and
CCR5, the predominant fusion coreceptor. Of note,
these cells express relatively low levels of CXCR4 [16].
Transmission of R5 viruses is strongly favored over X4
viruses; however, the underlying basis for the selection
of R5 viruses is unknown. The marked coexpression of
CCR5 and a4b7 along with the close physical association
of these two surface markers with CD4, on cells that are
highly susceptible to productive infection, may provide
at least in part an explanation for the strong bias
toward R5 virus transmission across mucosal surfaces.
It is important to note that, despite the high level
expression of CCR5 on this cellular subset, CCR5 is
effectively hidden from HIV-1 before engaging the
CD4 receptor. In contrast, a4b7 is a prominent receptor
( ~ 3t i m e st h es i z eo fC D 4 )( F i g2 )t h a tg p 1 2 0c a n
engage independently of CD4 [14,16]. Unlike CD4,
which is expressed uniformly on both resting and acti-
vated CD4
+ T cells, a4b7 is expressed at high levels pri-
marily on activated cells. In this manner a4b7 provides
a structural mechanism for HIV-1 to target activated
cells that express high levels of CCR5. Of note, analysis
of subtype C gp120s derived from early transmitted iso-
lates indicates that these gp120s require high levels of
CCR5 and CD4 [29]. Thus, the structural prominence
of a4b7 and its CD4-independent engagement of gp120,
combined with its selective expression on metabolically
activated [16] CCR5
high CD4
+ T cells provides a rational
basis for the HIV-1 envelope to have evolved a specific
affinity for a4b7.
Of note, dendritic cells may play an important role in
the selective transmission of R5 viral isolates via DC-T
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genital mucosa it is possible that antigen-specific T cells
responses that involve DCs interacting with a4b7
+ CD4
+
T cells promote infection of those CD4
+ Tc e l l s .I nt h i s
regard it is noteworthy that the antigen-specific
response to certain sexually transmitted diseases (STDs)
involves a4b7
+ CD4
+ T cells [17,19]. Because the great
majority of a4b7
+ CD4
+ T cells in the genital mucosa
express high levels of CCR5 it is reasonable to envision
that, in the contest of a STD-induced immune response,
DC-T cell interactions in the genital mucosa may pro-
mote infection of CD4
+ T-cells by R5 viruses.
Signaling mediated by gp120
a4b7 is closely associated with CD4, the HIV-1 entry
receptor, on CD4
+ T cells in GALT. The interaction
between gp120 and a4b7 triggers a signal, that is not yet
fully defined [14,16]; however, it has been reported that
the gp120-mediated signal transduction in several
cellular subsets impacts viral replication. In this regard,
a number of reports conclude that HIV-1 gp120 med-
iates signals that facilitate viral replication [32-36]. In
this regard, HIV-1 gp120 is a unique ligand that can
mediate signals in a near simultaneous manner through
CD4, a chemokine receptor and a4b7. The first gp120-
mediated signal to be reported involved a protein
tyrosine kinase. In response to gp120 treatment, CD4
+
T-cells rapidly phosphorylate p56lck, which then dis-
sociates from the cytoplasmic domain of CD4 [37]. The
identification of chemokine receptors as HIV corecep-
tors opened up new questions regarding the role of
chemokine receptor signaling in viral infection and
pathogenesis [3,4,38]. gp120 was shown to trigger rapid
calcium fluxes by engaging CCR5 [39]. There is some
evidence suggesting that the differential capacity of
genetically distinct gp120s to signal correlates with their
capacity to facilitate replication [32]. HIV-1 gp120
induces phosphorylation of several proteins, many
β7 CCR5 CD4 β7 CCR5 coloc
β7  CCR5  CD4 
DIC
Figure 1 On gut a4b7
high CD4
+ T cells a4b7 colocalizes with CD4 and CCR5. Freshly isolated gut cells obtained from biopsies taken from
healthy donors were stained with the a4b7 mAb Act-1 (red), the CD4 mAb OKT4 (purple), and the CCR5 mAb 2D7 (green) and viewed under a
confocal microscope. Unstained and individual stains of a representative cell are presented along with digitally defined regions of colocalization
between a4b7 and CD4 (yellow) and a4b7, CD4 and CCR5 (blue). This cell is representative of greater that 60 cells analyzed from four donors.
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[40] and FAK [41]. Binding of gp120 to both CCR5 and
CXCR4, activates several intracellular signaling cascades,
mimicking the natural ligands of the chemokine recep-
tors. HIV-1 gp120 has also been shown to trigger signal-
ing in resting cells. In resting cells gp120 mediates the
nuclear translocation of the transcription factor NFAT
that can enhance viral transcription by binding to
NFAT recognition sites on the HIV long terminal repeat
(LTR) [33]. gp120 can mediate chemotaxis, actin cytos-
keleton rearrangement [42] and the activation of an
actin depolymerization factor, cofilin, in resting cells
[43]. The density of cell surface CCR5 determines post-
entry efficiency of replication of an R5 virus [44] and in
unstimulated primary T cells, CCR5 signaling supports
HIV-1 infection [45]. Moreover, gp120-CCR5 signaling
can induce a distinct gene expression profile in primary
cells and a signaling cascade, associated with cellular
activation, that favors viral replication in non-proliferat-
ing target cells [33,34]. As noted above, R5 viruses dom-
inate the early stages of infection, largely infecting
activated memory CD4
+ T cells in the draining
lymphoid tissue, particularly the GALT [6,46-48]. Both
activated and “ostensibly resting” CD4
+ T cells are
involved in the early stages of infection in the GALT
[6]. The capacity of gp120 to trigger signals that pro-
mote viral replication in both activated and resting cells,
may facilitate infection. This activity may be particularly
important during mucosal transmission. Studies of
transmission in an SIV macaque model [6,47,49] indi-
cate that the first cells infected are not fully activated. It
is in these cells that gp120 signals may provide the
necessary metabolic stimulus to achieve productive
infection. Although our knowledge of gp120-a4b7 sig-
naling is incomplete, we can speculate that it is in this
setting that gp120-a4b7 signal transduction may play an
important role and may be a major factor in the trans-
mission of HIV at the mucosal surface.
Virological synapse
HTLV-1 was the first retrovirus shown to spread
through structures termed virological synapses (VS)
[50]. It is now recognized that HIV-1 also spreads effi-
ciently between T-lymphocytes across VS [51-56]. A VS
Figure 2 A schematic depicting approximate sizes of a4b7, CD4, and a gp160 trimer.
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synapse (IS) that is formed between an antigen present-
ing cells and T cells, an event that precedes T cell acti-
vation. Both IS and VS formation involves the dynamic
movement of receptors at the membrane interface, lead-
ing to the formation of a signalosome [57]. Both the IS
and the VS involve polarized structures that depend on
adhesion molecules and cytoskeleton remodeling. VS
allow efficient transfer of viral proteins from an infected
cell to an uninfected target cell [50,52,55,56]. The for-
mation of VS serves to promote a fast and potent signal-
ing cascade of phosphorylation events, Ca
++ flux and the
activation of several genes. There occurs a significant
active remodeling of the actin cytoskeleton that facili-
tates lateral mobility of receptors on the membrane.
Moreover, local actin remodeling stabilizes cell-cell con-
tacts and promotes efficient signal transmission [58-60].
Analogous mechanisms are likely at work in productive
HIV-1 spread between CD4
+ T-cells [61]. The similarity
between the HIV-1 envelope-mediated signaling events
a n dt h es i g n a l i n gi n v o l v e di nt h eI Sf o r m a t i o ni s
remarkable [57]. However, despite similarities to IS,
gp120-induced signaling mediates distinct membrane-
proximal events that cause only a partial activation of
canonical TCR signals [62,63]. It is therefore clear that
the synapse mediated by HIV-1 uses some, but not all
of the components of a classical IS.
Several reports are in agreement that HIV-1 transmis-
sion in T-lymphocytes cultures occurs predominantly
through cell-cell spread with an estimated efficiency
100-1000 times greater than cell free virus replication
[51,55,64-66]. The formation of an HIV-1 VS is facili-
tated by the interaction of envelope with CD4 and the
chemokine coreceptor [52,53]. Integral to HIV-1 VS are
adhesion molecules including LFA-1 and its ligand
ICAM. Of note, gp120-a4b7 interactions mediate a rapid
activation of LFA-1 [14] (Fig. 3a, 3b, 3c). It is important
to emphasize that cell-to-cell spread of HIV through VS
is far more efficient than cell free infection, and likely to
be an important means of viral replication in vivo.
HIV-1 envelope structure
The gp120 envelope glycoprotein of the HIV-1 pro-
motes virus entry by sequentially binding CD4 and che-
mokine receptors on the target cell. Primary clinical
HIV-1 isolates require an initial interaction with CD4
that induces conformation changes which allow gp120
to bind the CCR5 chemokine receptor in an efficient
way. HIV-1 gp120 is composed of 5 variable regions (V1
to V5), and 5 constant regions (C1 to C5) that are gen-
erally similar among different viral isolates. Among the
variable regions, disulfide bridges form the V1/V2 loop
domain that joins the V1 and V2 loops. The other vari-
able regions (V3, V4, V5) form independent loops in
gp120 [67]. Advances in our understanding of the struc-
ture and function of the variable and constant regions
of gp120 may provide insight into the design of a subu-
nit immunogen for an HIV vaccine [68].
The envelope is in a non-covalently associated trimer
of gp120/gp41 heterodimers. After gp120 binds CD4 it
undergoes an extensive conformational change that rear-
ranges both the gp120 core and the variable loops.
Among the better-defined conformational changes are
those involving the V3 loop [67]. Upon CD4 binding,
the V3 loop is exposed and engages the coreceptor
(CCR5 or CXCR4), which then mediates membrane
fusion. A region of gp120 termed the ”bridging sheet”
also interacts directly with the amino terminus of the
coreceptor. The HIV envelope structure exhibits a plas-
tic character and the variable loops contribute to this
flexibility [69,70]. The V1/V2 loop is generally exposed
on the envelope and is highly immunogenic. Of note, it
is one of the first targets of the early immune response,
and anti-V1/V2 Abs often have strong neutralizing
activity against autologous virus at a relatively early time
point after infection [71-74].
Several crystal structures of the core fragment of
gp120 have been solved [75-78], many of which are
m i s s i n gt h em o r ef l e x i b l ee l e m e n t ss u c ha sV 1 / V 2 ,V 3
loop, N- and C-terminal peptides as well as all of the
post-translationally added carbohydrates [75-78]. HIV-1
gp120 structures were originally determined in complex
with the D1D2 fragment of CD4 [77] or CD4 mimics
[79], whereas one SIV gp120 structure was solved in an
unliganded state [75]. Modeling on the crystal structure
of a gp120 core suggests that the V3 loop is partially
occluded by the V1/V2 loop when gp120 is in an unli-
ganded state [75]. Despite dramatic antigenic differences
between primary and laboratory-adapted HIV-1, key
structural features of their gp120 cores are remarkably
similar.
HIV-1 neutralization resistance is promoted by qua-
ternary interactions involving the major variable loops.
T h e r ei si n c r e a s i n ge v i d e n c et h a ts e q u e n c ev a r i a t i o ni n
the V1/V2 loop, and to a lesser extent V4 and V5 loops
mediates neutralization resistance [69,74,80-82]. This
variation occurs without serious detriment to the envel-
ope core structure [76]. It has been reported that
sequence variation in the V1/V2 loop plays an impor-
tant role in viral tropism and in the regulation of cell
entry [83-86]. Both the structure and function of the
V1/V2 loop domain is poorly understood. However, in
H I Vs u b t y p e sAa n dCt h e r ee x i s t sap o t e n t i a ll i n k
between V1/V2 loop glycosylation, length and virus
transmission [73,74,80,82,87-89]. In some studies,
sequence analysis of gp120s derived from transmission
pairs suggests that early-replicating isolates encode a
“transmission signature” that includes sequences within
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Figure 3 A schematic depicting the formation of a Virological Synapse (VS) upon engagement of a4b7 by HIV-1 envelope. An HIV-1
infected cell encounters a highly susceptible target cell expressing high levels of a4b7 (panel a). HIV-1 envelope on the surface of the infected
cell binds to a4b7 on the target cell and activates the downstream integrin LFA-1 (panel b). LFA-1 binds to its ligand ICAM-1 (panel c) and
stabilizes a VS.
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transmission [74,88,90]. The first biological function
assigned to the V1/V2 loop is the ability to bind to the
integrin a4b7on the surface of CD4+ T cells [14].
V1/V2 loop and transmission
Upon transmission across mucosal surfaces, the HIV
quasispecies replicating in an infected donor contracts
through a “genetic bottleneck” in the recipient, and
often infection results from a single infectious event
[89]. In some studies this genetic bottleneck does not
appear to be random, but rather involves a bias toward
the transmission of viruses encoding common genotypic
characteristics. In HIV subtypes A and C the genetic
signature of these founder/early transmitting viruses has
been mapped primarily to the V1/V2 loop, with addi-
tional sites in C3 and V4. The two features that are
most consistently overrepresented in early transmitting
viruses are compact/shorter V1/V2s with reduced num-
bers of N-linked glycosylation sites relative to the qua-
sispecies replicating in the plasma of donors at the time
of transmission [73,74,80,82,87-89]. It has been sug-
gested that these features increase, in some unknown
manner, the transmission fitness of founder viruses
[82,90]. Over time these genotypic features are diluted
as the quasispecies heterogeneity increases
[20,74,81,88,90]. Many questions surrounding the trans-
mission bottleneck remain unanswered. In particular,
there is no clear explanation as to how viruses encoding
shortened V1/V2s with fewer N-linked glycosylation
sites possess increased transmission fitness. In addition
it is unclear why such features are found in some
cohorts, but not others. Finally, it is unclear whether the
genotypic signature of early transmitting viruses is simi-
lar in all viral subtypes and whether these patterns hold
in all modes of transmission.
It is noteworthy that the genotypic signature of foun-
der/early transmitting vir u s e sm a p st ot h eV 1 / V 2l o o p
that also includes a key binding site for a4b7[14].
To the extent that a4b7-reactivity facilitates infection,
optimal a4b7 binding may, under certain conditions,
facilitate transmission. Transmission is a critical point at
which the virion must productively infect susceptible
target cells. Once this occurs, active replication foci are
established. This scenario has been termed the “broad-
cast” model of transmission [6,49]. The productive
infection of susceptible target cells is a critical step. At
this point in transmission, failure to infect highly sus-
ceptible cells will likely lead to an abortive transmission.
The very first step in infection is the engagement of cell
surface receptors by virion associated envelope spikes. If
contact occurs with a susceptible target cell, a cascade
of signals is triggered and a productive infection is
initiated. Although many details remain unknown, it is
reasonable to speculate that virions (or envelope spikes
on infected cells) are likely to first engage a4b7 and sub-
sequently engage CD4. a4b7 resides in close proximity
to CD4 on the surface of a T cell (Fig.1); however, it is
structurally more prominent, rising three times higher
of the surface of the cell than does CD4 (Fig. 2). The
gp120 V2-loop, which mediates binding to a4b7, is posi-
tioned near the apex of an envelope spike [91]. In this
way both a4b7 and its binding epitope on a virion spike
are well positioned for the initial engagement between
the virion and the target CD4
+ T cell.
HIV-1 Neutralizing antibody-responses target the
gp120 V1V2 loop
In general the neutralizing antibody responses to HIV-1
in vivo are of limited breadth [92]. This is particularly
true for the V1/V2 loop. Autologous neutralizing anti-
bodies against V1/V2 are frequently detected within
months following infection [69,71,73,74,80,81]. Such
responses, in many cases are potent and exert pressure
on the envelope of HIV. However, the structural flexibil-
ity of V1/V2 facilitates rapid neutralization escape. A
limited number of human broadly neutralizing mAbs
have been isolated [93]. All of these well-characterized
broadly neutralizing mAbs target the HIV-1 envelope.
An extensive analysis of these antibodies, including their
crystal structures has provided important information.
All of these mAbs exhibit unusual structural characteris-
tics. Recently, two broadly neutralizing mAbs, PG9 and
PG16, specific to the V1/V2 loop have been identified
[94]. The identification of the two mAbs, that target
conserved residues embedded within the variable loops
suggest that variable loops can be considered as poten-
tial targets for a gp120-based vaccine immunogen
[94,95].
Conclusion
In natural infection the HIV-1 envelope protein is the
primary target of neutralizing antibodies [67,96]. For
this reason HIV-1 gp120 has been a central focus of
efforts to develop subunit vaccine immunogens that can
elicit neutralizing antibodies. The receptor binding epi-
topes on gp120 are conserved, and antibodies directed
against these sites neutralize HIV-1, making receptor
binding sites attractive targets in the context of an
i m m u n o g e n .T h e s ee f f o r t sh a v ep r o v e nt ob ed i f f i c u l t
because the viral envelope uses multiple mechanisms to
evade and escape neutralizing responses. The envelope
protein is hyper-variable in sequence, both within a
patient and across each of the major clades. In addition
the envelope encodes a shifting pattern of glycosylation.
Finally, the flexibility of the variable loops results in
conformational masking of conserved epitopes. In parti-
cular, the CD4 binding site on gp120, which is
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loops. Thus, efforts to develop an immunogen capable
of eliciting broadly cross-reactive Abs against the CD4
binding site have thus far been unsuccessful.
Unlike the CD4 binding site that the HIV envelope
“hides” from antibodies, the a4b7 binding site in the
gp120 V1/V2-loop is likely to be accessible, and immu-
nogenic [70]. Moreover anti V1/V2-loop Ab responses
are able to neutralize autologous virus [70,73,74,97].
The challenge presented by V1/V2 is that the predomi-
nant neutralizing responses against this domain are
type-specific. V1/V2 readily escapes these responses
through genetic drift and selection. What remains to be
determined is whether conserved neutralizing epitopes
can be identified and used to develop an effective
immunogen. The potential utilization of a4b7 on suscep-
tible CD4+ T cell targets by early-transmitting gp120s
may hold important clues in this regard.
In conclusion, the specific affinity of gp120 for a4b7
may play a critical role in the infection of CD4
+ Tc e l l s
in mucosal tissues. a4b7 is not required for infection,
but appears to increase the efficiency of infection. More-
over, a4b7 is closely associated with CD4 on a subset of
CD4
+ T cells that express high levels of CCR5 and are
highly susceptible to infection. Signals delivered by
gp120 through all three receptors have the capacity to
promote productive infection. These observations sug-
gest that gp120 engagement of a4b7 facilitates infection
of CD4
+ T cells in the earliest stages of transmission. In
future studies it will be important to determine if anti-
body responses directed against the V1/V2 region of
gp120 can contribute to a protective immune response.
In this regard further understanding the structural and
functional interactions between V1/V2 and a4b7 may
provide important information for the design of gp120
subunit vaccines.
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